Abstract:
The second-most prevalent neurological disorder in the world, Parkinson's disease (PD) affected
roughly 6 million people as of 2016. The death and loss of dopaminergic neurons in the substantia
nigra pars compacta (SNpc) is the primary pathogenic characteristic of PD. Motor abnormalities
like limb stiffness, tremors, and bradykinesia are the major symptoms of PD. Parkinson's disease
remains an unsolved clinical problem, as currently, authorized PD therapies offer relatively modest
therapeutic benefits. In this study, mice models are utilized for PD induction by MPTP neurotoxin
for functional characterization of proteomic factor Neurexin 1. The effect of co-administering
clozapine drugs in MPTP mice models was analyzed through histological analyses, behavioural
evaluations, and RT-PCR. Results showed that mice treated with clozapine had considerably upregulated the expression of NRXN-1 in the brain than mice treated with MPTP. These findings
provide interesting directions for future approaches in establishing MPTP-induced neuronal injury
and shed light on the possible therapeutic implications of NRXN1 in reducing neurodegeneration
in Parkinson's disease along with studying the coherent expression of all three Neurexin genes.
